Research peptides in Australia: the substance is scheduled, so the label does not matter

Australia is the one major jurisdiction that regulates the research-peptide molecule rather than the claims made for it. Since June 1, 2024, BPC-157 has been a Schedule 4 substance in the Poisons Standard with an Appendix D entry that makes possession without authority an offence in its own right. Melanotan II is prescription-only and on no register. The Therapeutic Goods Administration declared unapproved peptides a national compliance priority on June 10, 2026, after a joint operation with the Australian Border Force and Victoria Police seized more than two million dollars of peptides, and on October 28, 2026 a Victorian coroner asked the agency to consider restricting two more. This is the country where the research label matters least, because the law looks past the label to the substance. This page sets out how that system works, how it was shaped by a sporting scandal a decade before the present market, what the enforcement record shows, and what it means for research material.

The Act: goods are regulated by what they are represented to be

The Therapeutic Goods Act 1989 covers goods that are represented in any way to be, or are likely to be taken to be, for use in or in connection with preventing, diagnosing or alleviating disease or in influencing or modifying a physiological process in people. Like Canada's statute, the definition turns on representation. Goods within it must be entered in the ARTG, the national register of approved goods, before they can be imported, manufactured, supplied or advertised, and the Act makes each of those acts an offence for unregistered goods, with civil and criminal penalties. No research peptide is on the Register. The TGA's own summary is one sentence long: It is unlawful to import, advertise, manufacture and supply unapproved peptide products in Australia.

There are exemptions, and each is narrow. The Special Access Scheme and the Authorised Prescriber scheme let a medical practitioner obtain an unapproved product for a named person or a class of them, with documentation. Pharmacists may compound a medicine for an individual on a prescription, which is the route through which peptides reached Australian clinics, and the route the coroner examined in the Norton findings. And the Personal Importation Scheme lets an individual import up to three months' supply of a medicine for their own use, provided that, where the substance is prescription-only in Australia, they hold a prescription from an Australian-registered prescriber. A Schedule 4 peptide without a prescription does not qualify, and the TGA says what happens next: shipments are intercepted at the border and destroyed.

The Poisons Standard: the substance is scheduled

What makes Australia different is the second layer. The Standard for the Uniform Scheduling of Medicines and Poisons places named substances in schedules, which the states and territories adopt into their own drugs and poisons law. Schedule 4 is prescription-only. Appendix D lists Schedule 4 substances subject to additional controls on possession or supply, and clause 5 of Appendix D is the list of substances whose possession without authority is itself illegal.

On May 22, 2024 the TGA's delegate published final decisions creating new entries for BPC-157 and capromorelin, and the Poisons Standard that took effect on June 1, 2024 placed both in Schedule 4 and Appendix D, clause 5 — BPC-157 and capromorelin, to provide that these substances are prescription-only medicines, possession of which without authority (e.g., other than in accordance with a legal prescription) is illegal. The explanatory statement lists BPC-157 among substances introduced in the current Poisons Standard for the first time. Before that date BPC-157 was unscheduled: a research chemical with no entry. After it, a vial of BPC-157 in Australia is a scheduled substance, and the only question is whether the person holding it has authority to.

That is the whole difference from the United States, the United Kingdom and Canada. In those systems a research-labeled vial is a chemical until a regulator infers, from claims and presentation, that it is a drug. In Australia, for BPC-157, the inference has been made once, in advance, for everyone. The label is not evidence to be weighed; it is irrelevant. Sport Integrity Australia's substance entry states the position in three lines: BPC-157 is Schedule 4, Appendix D, clause 5; it is not approved by the TGA; it is prohibited at all times in sport.

The TGA's alerts of April 2026 name BPC-157, GHK-Cu, TB-500 and CJC-1295 as examples of unapproved peptide products. Only BPC-157 among them has its own Appendix D entry; the others are caught by the Act's representation test and, where they are prescription-only by class, by Schedule 4. The direction is clear. The coroner's October 2026 recommendation asks the TGA to review the therapeutic benefits and safety risks of peptides such as CJC1295 and Ipamorelin and consider whether further restrictions ought to be imposed on their use, and the TGA has said it is considering whether further regulatory or other measures may be appropriate. More scheduling is the likely answer.

How sport wrote the rules first

Australia's peptide law was shaped by a sporting scandal a decade before the present market. On February 7, 2013 the Australian Crime Commission published Organised Crime and Drugs in Sport, the result of a twelve-month investigation that found peptides and other performance-enhancing substances being supplied to professional athletes through anti-ageing clinics, compounding pharmacies and online sellers. The same month the Essendon Football Club asked the AFL and the Australian Sports Anti-Doping Authority to investigate its own 2012 supplements program. The AFL's tribunal found thirty-four players not guilty on March 31, 2015. The World Anti-Doping Agency appealed, and on January 12, 2016 the Court of Arbitration for Sport found all thirty-four guilty of using thymosin beta-4, the peptide sold for research as TB-500, and suspended each for two years. The evidence showed the peptide had been dispensed by a compounding pharmacy.

Three things followed that still shape the Australian system. Sport Integrity Australia, the successor to ASADA, maintains public substance entries that state each peptide's Poisons Standard status alongside its sporting status, so the scheduling of a peptide is visible to anyone who looks it up. The TGA's enforcement against peptide sellers began in the same period and has run continuously since. And the compounding route, which Essendon's program used in 2012, is the route the TGA has been narrowing ever since, and the one the Norton findings put in question in 2026.

The enforcement record, 2019 to 2026

• July 2019. The Federal Court ordered a $10 million penalty against an online peptide clinic for unlawful advertising and supply of compounded prescription-only medicines through its website and social media. It remains the largest penalty in the Australian record.
• 2019 and 2020. Infringement notices to an online seller of selective androgen receptor modulators and melanotan II ($15,210), to a pharmacy for advertising peptides, SARMs, hormones and stem cells ($214,200 across seventeen notices), to a Victorian pharmacist ($30,240) and to a company advertising peptides as preventive against COVID-19 ($63,000).
• March 2024. A search warrant executed at a Melbourne pharmacy; peptides and an obesity medicine seized over alleged unlawful manufacture.
• April 2024 and September 2025. Individuals fined for importing unapproved peptides and prescription-only medicines without authority: $3,756, then three notices totaling $11,268. Importers, not only sellers, are fined.
• June 1, 2024. BPC-157 enters Schedule 4 and Appendix D, clause 5.
• April 2026. Two TGA safety alerts, to importers, compounders and suppliers of unapproved peptide products, warning that promoting them particularly through social media or influencer channels, is likely to breach Australian therapeutic goods advertising laws, and naming BPC-157, GHK-Cu, TB-500 and CJC-1295.
• May 2026. Twenty-seven infringement notices totaling $101,412 to a New South Wales individual for supplying melanotan II, paid that month. The TGA noted that no product containing melanotan II is on the Register.
• June 10, 2026. Unapproved peptides named a compliance priority. The TGA's head, Anthony Lawler: As the availability of unapproved peptide products has increased, so too has evidence of potential risk to consumers. A joint operation with the Australian Border Force and Victoria Police seized peptides and related products valued at more than $2 million.
• July 2026. The TGA says it is working directly with social media and e-commerce platforms to remove unlawful advertising, that advertising unapproved products directly to Australian consumers is generally prohibited, extending to websites, online marketplaces, social media posts, influencer content, affiliate marketing, and that influencers, affiliates, online sellers and anyone else promoting unapproved peptide products may be held accountable for unlawful advertising.
• August 2026. A raid on a New South Wales residence, the home of a social media influencer the TGA had warned before, seizing more than $120,000 of peptide and steroid products including CJC-1295 and a blend of BPC-157 and TB-500 sold under a nickname.
• October 28, 2026. The Coroners Court of Victoria's findings in the death of Richard Norton, with the recommendation that the TGA review peptide restrictions. See this library's piece on the findings.

The pattern is the opposite of the United Kingdom's. Britain closes websites and rarely fines. Australia fines individuals, importers and influencers, seizes at the border and destroys, and has a court penalty in eight figures on the record. The reason is structural: Australian law gives the regulator an offence for each act, import, supply, advertising and possession, and an infringement-notice power to use without going to court.

What this means for research material

For a laboratory, the Australian system is the clearest of the five, and the strictest. A scheduled peptide is held under the same state authority as any other Schedule 4 substance a laboratory keeps: a licence, permit or approval under the state's drugs and poisons law, which research institutions hold as a matter of course. Without it, possession of BPC-157 is an offence whatever the vial says. Import for research is a commercial import of a scheduled substance and follows the same permit route, not the Personal Importation Scheme. An unscheduled peptide is a chemical until the Act's representation test brings it under the Act, which happens the moment anyone represents it for use on the body.

What Australia has not done is act against a laboratory. Every action in the record above is against a seller, a pharmacy, a clinic, an importer for personal use or an influencer. The research-use line in Australia is enforced by scheduling, and scheduling is enforced at the border and against sellers. A research supplier outside Australia shipping a scheduled peptide to an Australian address without a permit is shipping to a parcel that will be destroyed, and a buyer who may be fined.

What to watch

• Whether the TGA acts on the coroner's recommendation by scheduling CJC-1295, ipamorelin or others into Appendix D, which would be the first scheduling driven by a death rather than by import referrals.
• The first prosecution under the June 2026 compliance priority, and whether it names a research-labeled seller.
• The Pharmacy Board's response on compounding of peptides, which the Norton findings put in question.
• Whether the states use the Appendix D entry against individual buyers, which the Standard permits and which no state has yet done publicly.

Frequently asked questions

Are research peptides legal in Australia?

It depends on the substance. BPC-157 is a Schedule 4 substance in Appendix D, clause 5 of the Poisons Standard, so possession without authority is an offence. Other peptides fall under the Act as unapproved goods the moment they are represented for use on the body, and importing, supplying or advertising them is unlawful. No research peptide is on the ARTG.

Is BPC-157 legal in Australia?

Only with authority: a prescription dispensed through the Special Access Scheme or an Authorised Prescriber, or a state licence to hold a Schedule 4 substance. Since June 1, 2024, possession without authority is illegal whatever the label says.

Can I import peptides into Australia for personal use?

Under the Personal Importation Scheme, only up to three months' supply and, for a Schedule 4 substance, only with an Australian prescription held at the time of import. Without it the TGA says shipments are intercepted and destroyed, and individuals have been fined for importing unapproved peptides.

Does "research use only" on the label mean anything in Australia?

For a scheduled substance, nothing: the schedule attaches to the molecule. For an unscheduled peptide, the Act's representation test applies, and the TGA's alerts make clear that promotion, including through influencers and affiliates, is what it acts on.

Who enforces peptide law in Australia?

The Therapeutic Goods Administration, with infringement notices, seizures and court proceedings; the Australian Border Force at the border; state and territory health departments under their drugs and poisons laws; the Pharmacy Board of Australia for compounding; and Sport Integrity Australia for athletes.

Sources & Further Reading

1. Therapeutic Goods Act 1989 (Cth), section 3 (definitions) and Chapter 3 (registration, listing and offences); the Regulations made under the Act (1990), Schedule 5 (exempt goods, including personal importation and extemporaneous compounding).
2. Poisons Standard—June 2024 instrument, F2024L00589, and its Explanatory Statement, May 30, 2024: Schedule 4 and Appendix D, clause 5 entries for BPC-157 and capromorelin; Therapeutic Goods Administration, Notice of final decisions to amend the current Poisons Standard, May 22, 2024.
3. Sport Integrity Australia, substance entry for BPC-157.
4. Therapeutic Goods Administration, safety alerts on unapproved peptide products, April 2026, as reported by newsGP (RACGP) and Pharmacy Daily, April 14, 2026; media release on twenty-seven infringement notices for supply of melanotan II, May 2026; media release naming unapproved peptides a compliance priority, June 10, 2026, as reported by ABC News the same day; media release on promoters and suppliers, July 2026, as reported by The Medical Republic, July 20, 2026; Pharmacy Daily, "TGA in peptide, melanotan raids", August 18, 2026.
5. Mills Oakley, "Peptides in Australia: recent TGA enforcement action", April 20, 2026, for the 2019 to 2025 infringement notices and the 2019 Federal Court penalty.
6. Australian Crime Commission, Organised Crime and Drugs in Sport, February 7, 2013; Court of Arbitration for Sport, WADA v. Thomas et al., award of January 12, 2016; AFL, timeline of the Essendon anti-doping case.
7. Coroners Court of Victoria, findings into the death of Richard Norton, October 28, 2026.

Cosmic Peptides. (2026, November 1). Research peptides in Australia: the substance is scheduled, so the label does not matter. Cosmic Peptides Research Library. Retrieved November 1, 2026, from https://cosmicpeptides.com/research/compliance/research-peptides-in-australia

@misc{cosmicpeptides_research_compliance_research_peptides_in_australia,
  author       = {{Cosmic Peptides}},
  title        = {Research peptides in Australia: the substance is scheduled, so the label does not matter},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = nov,
  url          = {https://cosmicpeptides.com/research/compliance/research-peptides-in-australia},
  urldate      = {2026-11-01},
  note         = {Last reviewed 2026-11-01}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - Research peptides in Australia: the substance is scheduled, so the label does not matter
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/11/01
UR  - https://cosmicpeptides.com/research/compliance/research-peptides-in-australia
Y2  - 2026/11/01
LA  - en
ER  -